Amarin Corp Plc (AMRN)

[Bouf]

KC: my sense is that the timing (recent FDA approval of R-IT label) will make the generics more inclined to play hardball right up to trial as they know AMRN needs to clear this litigation for a variety of reasons. But I think they will settle by time of the trial.